MBRX - Moleculin Biotech's annamycin shows encouraging action in animal study

Moleculin Biotech (MBRX) has announced additional preclinical data, demonstrating improved activity with liposomal annamycin against acute myeloid leukemia ((AML)) when used in combination with the commonly used antileukemic drug Ara-C (also referred to as cytarabine) versus single agent.In the study, median survival was ~13 days. For animals treated with the combination of Annamycin and Ara-C, median survival ranged from 56 to 76 days, thus expanding median survival by 585%, with some animals being completely cured.

For further details see:

Moleculin Biotech's annamycin shows encouraging action in animal study